TY - JOUR
T1 - Correction
T2 - Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial (Alzheimer's Research & Therapy, (2023), 15, 1, (39), 10.1186/s13195-023-01169-x)
AU - Dubois, Bruno
AU - López-Arrieta, Jesús
AU - Lipschitz, Stanley
AU - Doskas, Triantafyllos
AU - Spiru, Luiza
AU - Moroz, Svitlana
AU - Venger, Olena
AU - Vermersch, Patrick
AU - Moussy, Alain
AU - Mansfield, Colin D.
AU - Hermine, Olivier
AU - AB09004 Study Group Investigators
AU - Tsolaki, Magda
N1 - Publisher Copyright:
© The Author(s) 2023.
PY - 2023/12
Y1 - 2023/12
N2 - Following publication of the original article [1], the authors identified an error in the author name of Triantafyllos Doskas. The given name and family name were reversed. The incorrect author name is: Doskas Triantafyllos The correct author name is: Triantafyllos Doskas The author group has been updated above and the original article [1] has been corrected.
AB - Following publication of the original article [1], the authors identified an error in the author name of Triantafyllos Doskas. The given name and family name were reversed. The incorrect author name is: Doskas Triantafyllos The correct author name is: Triantafyllos Doskas The author group has been updated above and the original article [1] has been corrected.
UR - http://www.scopus.com/inward/record.url?scp=85153551932&partnerID=8YFLogxK
U2 - 10.1186/s13195-023-01230-9
DO - 10.1186/s13195-023-01230-9
M3 - Comment/Letter to the editor
C2 - 37087449
SN - 1758-9193
VL - 15
SP - 85
JO - Alzheimer's Research & Therapy
JF - Alzheimer's Research & Therapy
IS - 1
M1 - 85
ER -